[An initial experience of endotherine-1 dual-receptor blockade in the treatment of sustained pulmonary hypertension early after congenital cardiac surgery in infancy].
We report an initial experience of successful application of bosentan (BOS), a endotheline-1 dual-receptor blocker, in the treatment of sustained pulmonary hypertension (PH) early after surgical correction of congenital heart disease. Two infants (5 and 9-months-old girls undergone repair of complete atrioventricular septal defect and closure of ventricular septal defect, respectively) suffered from PH-relating symptoms after extubation despite oral sildenafil (SIL) treatment. After administration of BOS (1.5 mg/kg/day), the symptoms were dramatically relieved and SIL was uneventfully discontinued. Although BOS caused a transient increment of liver transaminase in the 5-month-old girl, BOS is a possible alternate in the treatment of the postoperative sustained PH as reported in a various type of chronic PH.
Nemoto
Shintaro
S
Department of Cardiovascular Surgery, Tenri Yorozu Soudansyo Hospital, Tenri, Japan.
Yoshimura
S
S
Matsumura
M
M
Nishimura
K
K
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D065130:Endothelin A Receptor Antagonists; D005260:Female; D006345:Heart Septal Defects, Ventricular / Q000601:surgery*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D007223:Infant; D011183:Postoperative Complications / Q000188:drug therapy; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D065130:Endothelin A Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan